US OptionsDetailed Quotes

STRO241220P7500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Nov 29 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Nov 1 07:03
    Update
    $Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
    Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
    Jaguar8
    Jaguar8
    Nov 1 07:02
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
    Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
    Jaguar8
    Jaguar8
    Oct 10 15:06
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
    Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
    Jaguar8
    Jaguar8
    Sep 14 02:03
    WEEKEND NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
    Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
    - 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
    - 35% overal...
    Jaguar8
    Jaguar8
    Aug 22 07:03
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
    Sutro Biopharma (NASDAQ: STRO) has initiated the REFRαME-L1 global Phase 2 study of luveltamab tazevibulin (luvelta) for non-small cell lung cancer (NSCLC)patients with Folate Receptor-α (FRα) expressing tumors.
    The trial is now open for enrollment, with initial data expected in H1 2025. Luvelta, an antibody drug conjugate (ADC), shows promise...
Read more